Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Caplacizumab in Adult aTTP (CAPLAVIE)
NCT04720261Phase 2Terminated
- Sponsor
- Rouen University Hospital
- Start
- Apr 2021
- Primary completion
- May 2023
- Modality
- Nanobodies (VHH)
- Countries
- 2
01
Overview
A Phase 2 trial of caplacizumab in thrombotic thrombocytopenic purpura (TTP), sponsored by Rouen University Hospital. Started Apr 2021; status: terminated.
02
Drugs
caplacizumab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NCT04720261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720261.